GlassScriptPhysician profile
Rebecca A Fox
NPI 1639351018
$11,219.75
in general payments reported to CMS, 2019-2025
34 companies · $6,621 in 2025
The $6,621 reported for 2025 was more than what 99% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $116 · 2023: $104 · 2024: $4,379 · 2025: $6,621.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K · Education: $235.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,868.37 |
| Education | $235.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,914.39 | 2024-2025 | |
| Janssen Biotech, INC. | $1,349.75 | 2024-2025 | Tremfya, Stelara, Simponi |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $970.23 | 2024-2025 | Xifaxan, Trulance, Relistor |
| Lilly USA, LLC | $670.28 | 2024-2025 | Omvoh |
| Qol Medical, LLC | $556.82 | 2024-2025 | Sucraid, Sucraid |
| Aimmune Therapeutics, INC. | $457.19 | 2025 | Zenpep |
| Genzyme Corporation | $448.03 | 2024-2025 | |
| Ardelyx, INC. | $445.95 | 2024-2025 | Ibsrela |
| Vivus LLC | $429.03 | 2024-2025 | Pancreaze |
| E.R. Squibb & Sons, L.L.C. | $344.19 | 2024 | Zeposia |
| Phathom Pharmaceuticals, INC. | $320.09 | 2024-2025 | Voquezna |
| Takeda Pharmaceuticals U.S.A., INC. | $292.80 | 2024-2025 | Entyvio, Eohilia |
| Madrigal Pharmaceuticals | $260.03 | 2024-2025 | Rezdiffra, Resmetirom |
| Regeneron Healthcare Solutions, INC. | $239.15 | 2024-2025 | Dupixent |
| Celltrion USA INC. | $205.17 | 2024-2025 | Vegzelma, Zymfentra |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $188.81 | 2025 | |
| Pfizer INC. | $179.90 | 2024-2025 | |
| Janssen Scientific Affairs, LLC | $148.92 | 2024 | Tremfya |
| Dova Pharmaceuticals | $116.00 | 2021 | |
| Blueprint Medicines Corporation | $112.32 | 2025 | Ayvakit |
| G1 Therapeutics, INC. | $103.88 | 2023 | Cosela |
| Organon LLC | $70.53 | 2024-2025 | Hadlima |
| Novo Nordisk INC | $61.74 | 2025 | Wegovy |
| Ferring Pharmaceuticals INC. | $56.41 | 2024-2025 | Rebyota |
| Ipsen Biopharmaceuticals, INC | $52.43 | 2025 | Iqirvo |
| Celgene Corporation | $48.20 | 2024 | Zeposia |
| Intercept Pharmaceuticals, INC. | $36.65 | 2024-2025 | |
| Evoke Pharma, INC. | $32.83 | 2024-2025 | |
| Sandoz INC. | $21.36 | 2024 | Hyrimoz |
| Eisai INC. | $20.46 | 2024 | |
| Invivyd INC | $17.57 | 2025 | Pemgarda |
| Exact Sciences Corporation | $17.31 | 2024 | Cologuard Collection Kit |
| Fresenius Kabi USA, LLC | $16.51 | 2024 | Idacio |
| Alnylam Pharmaceuticals INC. | $14.82 | 2024 | Givlaari |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rebecca Fox listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.